Vancomycin resistant staphylococcus aureus infection (vrsa) market: evolving market trends & dynamics 2024

1. Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market:
Evolving Market Trends & Dynamics 2024
Date: 03-01-2017 12:10 AM CET
Category: Health & Medicine
Press release from: Transparency Market Research - Pharmaceutical
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Brief Description
Staphylococcus aureus is an anaerobic gram positive bacteria, commonly found in the respiratory tract of human and on the
skin. This strain of bacteria is always not pathogenic but remains a major cause for respiratory diseases, skin infections and
food poisoning. S.aureus strains often promote infections by producing harmful protein toxins. It is anticipated that
approximately 20% of the population carries S.aureus in the anterior part of nasal passages and in the skin flora. Among all the
strains of staphylococcus, S.aureus is one of the most common species that cause Staph infection and cause range of illness
such as impetigo, boils, pimples, skin infections, abscesses and other life threatening diseases such as meningitis, pneumonia,
sepsis, osteomyelitis and others. S.aureus infection remains one of the most common causes of postsurgical wound infection
and nosocomial infections. Penicillin is the most common choice witnessed for the treatment of S.aureus infection but
development of resistance from penicillin is commonly seen hence, a combination therapy along with gentamicin is prescribed
for the treatment of infections. In addition, currently some of the strains have developed resistance to B-Lactam antibiotics
which are termed as Methicillin resistant S.aureus (MRSA). This type of infection is growing at a rapid rate and is most often
found in hospitals, clinics and in community regions.
Browse Global Strategic Business Report:
www.transparencymarketresearch.com/vancomycin-resistant-s...
Likewise, vancomycin resistant Staphylococcus aureus refers to the strains of S.aureus that have become resistant antibiotic
glycopeptides (vancomycin). Presently three classes of vancomycin-resistant S.aureus (VRSA) have emerged namely high
level VRSA, vancomycin-intermediate S.aureus (VISA) and heterogenus VISA (hVISA). VISA infection was firstly identified
in Japanese hospitals however, later this strain of bacteria is also found in the Asian region. Linezolid, Ceftobiprole,
daptomycin, tigercycline and others are the major drugs prescribed for the treatment of VISA infection. VRSA infection
usually reported in people having weakened immune system or to those who are taking vancomycin for a longer duration. The
infection is also seen in those people who have undergone surgical procedures.
Seite 1 / 3

2. Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Trends and Prospects
The market for vancomycin resistant Staphylococcus Aureus is increasing due to rising incidences of the infection.
Additionally, growth in government and non government awareness program are also other major factors that are expected to
drive the growth of this market. For instance, Centers for Disease Control and Prevention is constantly working with the
healthcare facilities, state local health agencies and clinical microbiology agencies. VRSA infections can be treated with
various commercially available antibiotics however, most efficient way of controlling the spread of VRSA is maintaining
basic hygienic conditions such as proper wound care, washing hands before while contacting directly with the patients and use
of disposable gloves.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Regional Overview
Geographically, North America and Europe dominates the vancomycin resistant Staphylococcus Aureus market due to rising
incidences of VRSA incidences and demand for new innovative drugs. However, during the forecast period these regions are
expected to show slow growth due to market maturity, shortened drug lifecycle and generic infiltration. Asia-pacific region is
anticipated to emerge as the fastest growing region in the near future due to growing number of pharmaceutical manufacturers
in the Asian countries and also due to the presence of some of the world’s leading generics manufacturers in this region.
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Key Players
AstraZeneca Plc, GlaxoSmithKline, Forest Laboratories, Cubist Pharmaceuticals and others are some of the major players
operating in this market.
Download Exclusive Brochure of This Report :
www.transparencymarketresearch.com/sample/sample.php?flag...
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and
services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of
decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various
tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable
information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food &
beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep
segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive
to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com
Seite 2 / 3

3. You can find this press release here
Seite 3 / 3